Stock IMP IMEXPHARM CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Imexpharm Corporation

Equities

IMP

VN000000IMP0

Pharmaceuticals

End-of-day quote Ho Chi Minh S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
64,500 VND -0.92% Intraday chart for Imexpharm Corporation -6.93% +13.96%
Apr. 19 Imexpharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jan. 19 Imexpharm Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,370,593 3,753,609 5,187,048 4,013,628 3,962,167 4,515,300 - -
Enterprise Value (EV) 1 2,370,593 3,753,609 5,187,048 4,013,628 3,962,167 4,572,300 4,515,300 4,515,300
P/E ratio - 20.3 x 29.9 x 17.2 x 15.6 x 13.3 x - -
Yield 2.08% 2.66% 1.93% - - - - -
Capitalization / Revenue 1.69 x 2.74 x 4.1 x 2.44 x 1.99 x 2.06 x - -
EV / Revenue 1.69 x 2.74 x 4.1 x 2.44 x 1.99 x 2.09 x - -
EV / EBITDA 9,583,362 x 12,155,380 x 17,332,265 x - 8,669,024 x - - -
EV / FCF - - - 14.4 x - 18.1 x 14.5 x 13.1 x
FCF Yield - - - 6.96% - 5.51% 6.91% 7.62%
Price to Book 1.52 x 2.17 x 2.89 x 2.11 x 1.9 x - - -
Nbr of stocks (in thousands) 67,414 70,005 70,005 70,005 70,003 70,005 - -
Reference price 2 35,165 53,619 74,095 57,333 56,600 64,500 64,500 64,500
Announcement Date 1/20/20 1/19/21 1/20/22 1/17/23 1/19/24 - - -
1VND in Million2VND
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,402,454 1,369,422 1,266,597 1,643,707 1,994,037 2,190,000 - -
EBITDA 247,366 308,802 299,271 - 457,049 - - -
EBIT 1 184,427 252,540 234,475 300,992 374,407 449,000 497,000 546,000
Operating Margin 13.15% 18.44% 18.51% 18.31% 18.78% 20.5% - -
Earnings before Tax (EBT) 1 - 255,441 238,859 301,763 377,273 426,000 - -
Net income 1 - 209,697 189,095 233,964 299,556 339,500 - -
Net margin - 15.31% 14.93% 14.23% 15.02% 15.5% - -
EPS 2 - 2,641 2,476 3,329 3,637 4,863 - -
Free Cash Flow 1 - - - 279,250 - 252,000 312,000 344,000
FCF margin - - - 16.99% - 11.51% - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - 119.36% - 74.23% - -
Dividend per Share 732.6 1,429 1,429 - - - - -
Announcement Date 1/20/20 1/19/21 1/20/22 1/17/23 1/19/24 - - -
1VND in Million2VND
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q1 2023 Q2
Net sales 1 479,272 439,691
EBITDA - -
EBIT 1 - 99,157
Operating Margin - 22.55%
Earnings before Tax (EBT) 1 - 100,003
Net income 1 - 79,675
Net margin - 18.12%
EPS 978.1 -
Dividend per Share - -
Announcement Date 4/18/23 7/18/23
1VND in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 57,000 - -
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - 279,250 - 252,000 312,000 344,000
ROE (net income / shareholders' equity) 10.6% 12.8% 9.32% 12.6% 15.1% 15.3% - -
ROA (Net income/ Total Assets) 8.97% 10.6% 8.61% 10.2% 12.8% 13.9% - -
Assets 1 - 1,971,818 2,195,579 2,291,096 2,334,809 2,442,446 - -
Book Value Per Share 23,124 24,719 25,633 27,210 29,778 - - -
Cash Flow per Share - - - - - - - -
Capex 1 133,036 89,685 52,857 99,353 - 72,000 79,000 87,000
Capex / Sales 9.49% 6.55% 4.17% 6.04% - 3.29% - -
Announcement Date 1/20/20 1/19/21 1/20/22 1/17/23 1/19/24 - - -
1VND in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
64,500 VND
Average target price
77,033 VND
Spread / Average Target
+19.43%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
IMEXPHARM CORPORATION Stock Imexpharm Corporation
+13.96% 178M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IMP Stock
  4. Financials Imexpharm Corporation